Plain-English fact sheet
Sermorelin
Also known as Geref, sermorelin acetate
Sermorelin was used in a former FDA-approved product that is discontinued from marketing; currently marketed compounded sermorelin products are not FDA approved.
Quick answer
Sermorelin is not currently available as an FDA-approved marketed drug product. The former Geref product was discontinued, and that history does not make current compounded versions FDA approved.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Sermorelin?
Sermorelin is a manufactured fragment of growth hormone-releasing hormone that can stimulate growth-hormone release from the pituitary gland.
A former branded product, Geref, had approved diagnostic and pediatric uses before being discontinued from marketing.
Why are people interested in it?
It is frequently promoted in anti-aging and body-composition contexts.
Those marketing claims need to be separated from the discontinued product's regulatory history and the limited evidence for today's promoted uses.
Current regulatory status
The FDA-approved Geref product is discontinued from marketing. Current compounded sermorelin products are not FDA-approved drug products, and discontinuation history should be checked in Drugs@FDA.
What is it approved for?
No FDA-approved use. This matters because clinical-trial participation and products marketed online are not the same as an approved medicine.
What is it being studied for?
Investigational areas
- Various growth-hormone-pathway outcomes outside a currently marketed FDA-approved product
Evidence snapshot
Human physiology and the former product are documented, but high-quality evidence for many current wellness, anti-aging, or body-composition claims is limited or unclear.
Potential benefits being researched
- Sermorelin can stimulate the growth-hormone pathway, which explains its historical diagnostic role.
- A biological effect does not by itself prove meaningful anti-aging, weight, or performance benefits.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- Current compounded products do not undergo FDA premarket review for safety, effectiveness, or quality.
- Potential effects of stimulating the growth-hormone pathway can matter for glucose control, fluid retention, and other health conditions.
- Product purity, sterility, strength, and labeling are separate concerns for unapproved products.
What we still do not know
- Long-term safety for commonly promoted off-label wellness goals
- Reliable benefits for anti-aging or body-composition claims
- Consistency and quality of products outside an approved drug application
Plain-English takeaway
Sermorelin's past approval does not confer approval on products sold today. Current claims should be evaluated against current product status and human evidence.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1FDA Drugs@FDA search: sermorelin
Official FDA approval records, labels, and regulatory history.
- 2FDA review noting Geref discontinuation
FDA clinical pharmacology review referencing the discontinued Geref product.
- 3ClinicalTrials.gov studies: sermorelin
Current and completed registered clinical studies.
- 4PubMed research: sermorelin
Peer-reviewed literature indexed by the National Library of Medicine.